Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021.
Questions
- What are the challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF)? (0.26)
- What is the mechanism of action of riociguat, and what clinical evidence supports its use in pulmonary hypertension associated with HFpEF? (1.39)
- What were the aims, design and eligibility criteria of the DYNAMIC study? (2.33)
- What were the efficacy and safety findings of the study? (3.38)
- What were the investigator’s conclusions and what further studies are planned? (4.08)
Speaker disclosures: Prof. Diana Bronderman has received speaker honoraria and research grants from Bayer, MSD, Pfizer, Janssen, Ionis, Alnylam, Zoll, Novartis, Boehringer Ingelheim and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Professor Diana Bonderman as a highlight of ESC 2021, August 2021.
